Esperion Therapeutics Inc (ESPR) 67.13 $ESPR
3 All-or-Nothing Biotech Stocks We're Closely Watching
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:10AM CST
There may be no other industry as prone to hit-or-miss investments as biotechnology. An astounding 90% of drugs that enter phase 1 clinical trials never reach commercialization, and that means failure is far more common than success. As a result,...
JNJ: 99.62 (+1.18), ESPR: 67.13 (-0.33), GERN: 3.03 (unch), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), PBYI: 205.26 (+2.75)
Esperion Therapeutics (ESPR) Jumps: Stock Rises 15.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:51AM CST
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise almost 16% on the day.
ESPR: 67.13 (-0.33), IG: 10.57 (-0.12)
Why Esperion Therapeutics Inc. Shares Skyrocketed Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 03, 2:00PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Esperion Therapeutics surged by more than...
ESPR: 67.13 (-0.33), MRK: 58.81 (-0.07)
Esperion on go for longer studies of cholesterol-lowering med
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 7:19AM CST
ESPR: 67.13 (-0.33)
Update: ETC-1002 Development Remains On Track
Mark Chapman - at Seeking Alpha - Tue Feb 03, 2:48AM CST
ESPR: 67.13 (-0.33)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 4:35PM CST
EGLE: 9.98 (-0.02), RCII: 30.49 (+0.92), ESPR: 67.13 (-0.33), FN: 16.94 (+0.02), TZA: 11.10 (-0.22), DDD: 32.81 (+0.40), SSYS: 67.16 (-0.34), TRGP: 93.93 (+0.69), CLF: 7.00 (+0.35), IDTI: 20.56 (-0.38)
Esperion Therapeutics Announces Removal of PPAR Partial Clinical Hold for ETC-1002
Marketwired - Mon Feb 02, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardio-metabolic risk markers, today announced the U.S. Food and Drug Administration (FDA) has removed the peroxisome proliferator-activated receptor (PPAR) partial clinical hold on ETC-1002. The action by the FDA will now allow Esperion to conduct clinical trials exceeding six months in duration.
ESPR: 67.13 (-0.33)
Jim Cramer's Top Stock Picks: MNST ESPR CRL
at The Street - Thu Jan 15, 5:00AM CST
Cramer says there's a lot to like about Monster Beverage and Esperion Therapeutics has some exciting cholesterol treatments under development.
MNST: 117.74 (-1.77), ESPR: 67.13 (-0.33), CRL: 73.61 (-0.33)
Cramer's Mad Money: Dogs And Cats (1/14/15)
SA Editor Michael Hopkins - at Seeking Alpha - Thu Jan 15, 12:05AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, January 14. Need to figure out the market? Look no further than the household pet. In his show Wednesday, Cramer said the unpredictable market action...
NFLX: 466.10 (+9.37), KO: 41.99 (-0.18), MNST: 117.74 (-1.77), ESPR: 67.13 (-0.33), CAT: 85.13 (+1.60), CRL: 73.61 (-0.33), OAS: 16.84 (-0.03)
Jim Cramer's 'Mad Money' Recap: Will You Still Hate the Markets Tomorrow?
at The Street - Wed Jan 14, 7:22PM CST
Cramer wonders how the markets that were so loved just a few weeks ago could be so hated this week.
KO: 41.99 (-0.18), CY: 14.76 (+0.01), MNST: 117.74 (-1.77), TK: 46.69 (+1.36), NXPI: 84.79 (-0.60), ADBE: 76.51 (+1.92), VEEV: 30.12 (+0.17), SBUX: 91.58 (-0.24), ESPR: 67.13 (-0.33), TSO: 81.92 (+0.50), PZZA: 62.11 (-1.11), NAT: 10.20 (+0.10), DPZ: 100.00 (-0.56), SYRG: 11.87 (-0.12), CRL: 73.61 (-0.33), STM: 8.91 (-0.21)
Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
at The Street - Tue Jan 06, 7:25PM CST
The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.
TSLA: 203.77 (+0.89), GE: 25.15 (+0.26), OVAS: 44.32 (+0.87), NMM: 12.37 (+0.24), XOM: 93.37 (+1.00), T: 34.66 (+0.05), ESPR: 67.13 (-0.33), IBM: 160.40 (+1.88), IRE: 14.54 (+0.81), DTV: 87.51 (-0.32), PTCT: 53.37 (-0.74), RCPT: 115.83 (-0.66), TEG: 75.56 (-1.61), PPG: 236.77 (+3.74), WAG: 76.05 (-0.49), BLUE: 90.70 (+0.93), TGTX: 13.13 (-0.19), WFC: 55.33 (+0.47), BA: 149.73 (+1.64), RAD: 8.34 (+0.25), ISIS: 63.86 (-0.43), RNA: 18.65 (unch), ACHN: 10.89 (-0.20), JCP: 8.05 (+0.14), CVS: 102.63 (-0.37), MCD: 95.65 (+0.56), AGIO: 118.55 (+0.11), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21), FOLD: 8.36 (-0.11)
Esperion Therapeutics to Present at 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 05, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that president and chief executive officer, Tim M. Mayleben, will present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12, 2015 at 8:30 a.m. Pacific Time/11:30 a.m. Eastern Time.
ESPR: 67.13 (-0.33), JPM: 59.67 (+0.10)
Esperion Therapeutics (ESPR) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 6:26AM CST
Esperion Therapeutics (ESPR) Shares March Higher, Can It Continue?
ESPR: 67.13 (-0.33)
Esperion Therapeutics: ETC-1002 Is Appealing, But The Valuation Is Not
Mark Chapman - at Seeking Alpha - Tue Dec 30, 6:22AM CST
ESPR: 67.13 (-0.33), MRK: 58.81 (-0.07), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Midday Gainers /Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 11:45AM CST
NICK: 14.91 (unch), JRJC: 5.46 (+0.16), OCN: 9.10 (+0.09), ZAZA: 2.17 (+0.08), VNDA: 12.37 (unch), EPAX: 2.45 (+0.04), FES: 1.19 (+0.06), NQ: 3.95 (-0.03), TECU: 3.07 (-0.02), VRML: 2.08 (+0.12), MYOS: 5.45 (-0.20), PME: 2.42 (-0.07), ESPR: 67.13 (-0.33), ALNY: 95.54 (+1.67), IDSA: 5.82 (-0.08), PRLS: 6.96 (-0.02), ACHN: 10.89 (-0.20), SKYS: 10.55 (-0.65), RCPT: 115.83 (-0.66), AGIO: 118.55 (+0.11)
Hypercholesterolemia - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/5snkwx/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Amgen - Eli Lilly and Company - Merck & Co - Pfizer - Santaris Pharma - SoluBest - Alnylam Pharmaceuticals - Regeneron Pharmaceuticals - CrystalGenomics - Catabasis Pharmaceuticals - Planet Biotechnology - Zhejiang Hisun Pharmaceutical - Esperion Therapeutics - Progenra - Serometrix - Hanmi Pharmaceuticals - AtheroNova. - Immune Response BioPharma - Agilvax - Michigan Life Therapeutics - LondonPharma - Dybly For more information visit http://www.researchandmarkets.com/research/5s...lesterolem
JNJ: 99.62 (+1.18), ESPR: 67.13 (-0.33), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), REGN: 402.40 (+0.66)
CORRECTION - Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 7:05PM CST
In a release issued under the same headline earlier today by The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) the ticker and exchange for Esperion Therapeutics, Inc. should read (Nasdaq:ESPR) (sted Nasdaq:EXPR).
ESPR: 67.13 (-0.33), NDAQ: 49.48 (-0.27)
Can the Rally in Esperion Therapeutics (ESPR) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:21AM CST
Can the Rally in Esperion Therapeutics (ESPR) Shares Continue?
ESPR: 67.13 (-0.33)
Surging Earnings Estimates Signal Good News for Esperion Therapeutics (ESPR) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 7:50AM CST
Esperion Therapeutics is seeing solid activity on the earnings estimate revision and has decent short-term momentum. The stock has also started to move higher lately, adding 20.5% over the past four weeks.
ESPR: 67.13 (-0.33)
3 All-or-Nothing Biotech Stocks We're Closely Watching
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:10AM CST
There may be no other industry as prone to hit-or-miss investments as biotechnology. An astounding 90% of drugs that enter phase 1 clinical trials never reach commercialization, and that means failure is far more common than success. As a result,...
JNJ: 99.62 (+1.18), ESPR: 67.13 (-0.33), GERN: 3.03 (unch), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), PBYI: 205.26 (+2.75)
Esperion Therapeutics (ESPR) Jumps: Stock Rises 15.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:51AM CST
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise almost 16% on the day.
ESPR: 67.13 (-0.33), IG: 10.57 (-0.12)
Why Esperion Therapeutics Inc. Shares Skyrocketed Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 03, 2:00PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Esperion Therapeutics surged by more than...
ESPR: 67.13 (-0.33), MRK: 58.81 (-0.07)
Esperion on go for longer studies of cholesterol-lowering med
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 7:19AM CST
ESPR: 67.13 (-0.33)
Update: ETC-1002 Development Remains On Track
Mark Chapman - at Seeking Alpha - Tue Feb 03, 2:48AM CST
ESPR: 67.13 (-0.33)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 4:35PM CST
EGLE: 9.98 (-0.02), RCII: 30.49 (+0.92), ESPR: 67.13 (-0.33), FN: 16.94 (+0.02), TZA: 11.10 (-0.22), DDD: 32.81 (+0.40), SSYS: 67.16 (-0.34), TRGP: 93.93 (+0.69), CLF: 7.00 (+0.35), IDTI: 20.56 (-0.38)
Esperion Therapeutics Announces Removal of PPAR Partial Clinical Hold for ETC-1002
Marketwired - Mon Feb 02, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardio-metabolic risk markers, today announced the U.S. Food and Drug Administration (FDA) has removed the peroxisome proliferator-activated receptor (PPAR) partial clinical hold on ETC-1002. The action by the FDA will now allow Esperion to conduct clinical trials exceeding six months in duration.
ESPR: 67.13 (-0.33)
Jim Cramer's Top Stock Picks: MNST ESPR CRL
at The Street - Thu Jan 15, 5:00AM CST
Cramer says there's a lot to like about Monster Beverage and Esperion Therapeutics has some exciting cholesterol treatments under development.
MNST: 117.74 (-1.77), ESPR: 67.13 (-0.33), CRL: 73.61 (-0.33)
Cramer's Mad Money: Dogs And Cats (1/14/15)
SA Editor Michael Hopkins - at Seeking Alpha - Thu Jan 15, 12:05AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, January 14. Need to figure out the market? Look no further than the household pet. In his show Wednesday, Cramer said the unpredictable market action...
NFLX: 466.10 (+9.37), KO: 41.99 (-0.18), MNST: 117.74 (-1.77), ESPR: 67.13 (-0.33), CAT: 85.13 (+1.60), CRL: 73.61 (-0.33), OAS: 16.84 (-0.03)
Jim Cramer's 'Mad Money' Recap: Will You Still Hate the Markets Tomorrow?
at The Street - Wed Jan 14, 7:22PM CST
Cramer wonders how the markets that were so loved just a few weeks ago could be so hated this week.
KO: 41.99 (-0.18), CY: 14.76 (+0.01), MNST: 117.74 (-1.77), TK: 46.69 (+1.36), NXPI: 84.79 (-0.60), ADBE: 76.51 (+1.92), VEEV: 30.12 (+0.17), SBUX: 91.58 (-0.24), ESPR: 67.13 (-0.33), TSO: 81.92 (+0.50), PZZA: 62.11 (-1.11), NAT: 10.20 (+0.10), DPZ: 100.00 (-0.56), SYRG: 11.87 (-0.12), CRL: 73.61 (-0.33), STM: 8.91 (-0.21)
Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
at The Street - Tue Jan 06, 7:25PM CST
The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.
TSLA: 203.77 (+0.89), GE: 25.15 (+0.26), OVAS: 44.32 (+0.87), NMM: 12.37 (+0.24), XOM: 93.37 (+1.00), T: 34.66 (+0.05), ESPR: 67.13 (-0.33), IBM: 160.40 (+1.88), IRE: 14.54 (+0.81), DTV: 87.51 (-0.32), PTCT: 53.37 (-0.74), RCPT: 115.83 (-0.66), TEG: 75.56 (-1.61), PPG: 236.77 (+3.74), WAG: 76.05 (-0.49), BLUE: 90.70 (+0.93), TGTX: 13.13 (-0.19), WFC: 55.33 (+0.47), BA: 149.73 (+1.64), RAD: 8.34 (+0.25), ISIS: 63.86 (-0.43), RNA: 18.65 (unch), ACHN: 10.89 (-0.20), JCP: 8.05 (+0.14), CVS: 102.63 (-0.37), MCD: 95.65 (+0.56), AGIO: 118.55 (+0.11), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21), FOLD: 8.36 (-0.11)
Esperion Therapeutics to Present at 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 05, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that president and chief executive officer, Tim M. Mayleben, will present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12, 2015 at 8:30 a.m. Pacific Time/11:30 a.m. Eastern Time.
ESPR: 67.13 (-0.33), JPM: 59.67 (+0.10)
Esperion Therapeutics (ESPR) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 6:26AM CST
Esperion Therapeutics (ESPR) Shares March Higher, Can It Continue?
ESPR: 67.13 (-0.33)
Esperion Therapeutics: ETC-1002 Is Appealing, But The Valuation Is Not
Mark Chapman - at Seeking Alpha - Tue Dec 30, 6:22AM CST
ESPR: 67.13 (-0.33), MRK: 58.81 (-0.07), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Midday Gainers /Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 11:45AM CST
NICK: 14.91 (unch), JRJC: 5.46 (+0.16), OCN: 9.10 (+0.09), ZAZA: 2.17 (+0.08), VNDA: 12.37 (unch), EPAX: 2.45 (+0.04), FES: 1.19 (+0.06), NQ: 3.95 (-0.03), TECU: 3.07 (-0.02), VRML: 2.08 (+0.12), MYOS: 5.45 (-0.20), PME: 2.42 (-0.07), ESPR: 67.13 (-0.33), ALNY: 95.54 (+1.67), IDSA: 5.82 (-0.08), PRLS: 6.96 (-0.02), ACHN: 10.89 (-0.20), SKYS: 10.55 (-0.65), RCPT: 115.83 (-0.66), AGIO: 118.55 (+0.11)
Hypercholesterolemia - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/5snkwx/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Amgen - Eli Lilly and Company - Merck & Co - Pfizer - Santaris Pharma - SoluBest - Alnylam Pharmaceuticals - Regeneron Pharmaceuticals - CrystalGenomics - Catabasis Pharmaceuticals - Planet Biotechnology - Zhejiang Hisun Pharmaceutical - Esperion Therapeutics - Progenra - Serometrix - Hanmi Pharmaceuticals - AtheroNova. - Immune Response BioPharma - Agilvax - Michigan Life Therapeutics - LondonPharma - Dybly For more information visit http://www.researchandmarkets.com/research/5s...lesterolem
JNJ: 99.62 (+1.18), ESPR: 67.13 (-0.33), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), REGN: 402.40 (+0.66)
CORRECTION - Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 7:05PM CST
In a release issued under the same headline earlier today by The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) the ticker and exchange for Esperion Therapeutics, Inc. should read (Nasdaq:ESPR) (sted Nasdaq:EXPR).
ESPR: 67.13 (-0.33), NDAQ: 49.48 (-0.27)
Can the Rally in Esperion Therapeutics (ESPR) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:21AM CST
Can the Rally in Esperion Therapeutics (ESPR) Shares Continue?
ESPR: 67.13 (-0.33)
Surging Earnings Estimates Signal Good News for Esperion Therapeutics (ESPR) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 7:50AM CST
Esperion Therapeutics is seeing solid activity on the earnings estimate revision and has decent short-term momentum. The stock has also started to move higher lately, adding 20.5% over the past four weeks.
ESPR: 67.13 (-0.33)
